Literature DB >> 31414295

MRI-Based Use of Neoadjuvant Chemoradiotherapy in Rectal Carcinoma: Surgical Quality and Histopathological Outcome of the OCUM Trial.

Martin E Kreis1, Reinhard Ruppert2, Rainer Kube3, Joachim Strassburg4, Andreas Lewin5, Joerg Baral6, Christoph A Maurer7,8, Joerg Sauer9, Günther Winde10, Rena Thomasmeyer11, Sigmar Stelzner12, Cornelius Bambauer13, Soenke Scheunemann14, Axel Faedrich15, Theodor Junginger16, Paul Hermanek17, Susanne Merkel17.   

Abstract

BACKGROUND: Preoperative magnetic resonance imaging (MRI) allows highly reliable imaging of the mesorectal fascia (mrMRF) and its relationship to the tumor. The prospective multicenter observational study OCUM uses these findings to indicate neoadjuvant chemoradiotherapy (nCRT) in rectal carcinoma.
METHODS: nCRT was indicated in patients with positive mrMRF (≤ 1 mm) in cT4 and cT3 carcinomas of the lower rectal third.
RESULTS: A total of 527 patients (60.2%) underwent primary total mesorectal excision, and 348 patients (39.8%) underwent long-term nCRT followed by surgery. The mrMRF was involved in 4.6% of the primary surgery group and 80.7% of the nCRT group. Rates of resections within the mesorectal plane (90.8%), sparing of pelvic nerves on both sides (97.8%), and number of regional lymph nodes (95.3% with ≥ 12 lymph nodes examined) are indicative of high-quality surgery. Resection was classified as R0 in 98.3%, the pathological circumferential resection margin (pCRM) was negative in 95.1%. Patients in the nCRT group had more advanced carcinomas with a significantly higher rate of abdominoperineal excision. Independent risk factors for pCRM positivity were advanced stage (T4), metastatic lymph nodes, resection in the muscularis propria plane, and location in the lower third.
CONCLUSIONS: The risk classification of rectal cancer patients by MRI seems to be highly reliable and allows the restriction of nCRT to approximately half of the patients with clinical stage II and III rectal carcinoma, provided there is a high-quality MRI diagnostic protocol, high-quality surgery, and standardized examination of the resected specimen.

Entities:  

Mesh:

Year:  2019        PMID: 31414295     DOI: 10.1245/s10434-019-07696-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  3 in total

1.  Association of certification, improved quality and better oncological outcomes for rectal cancer in a specialized colorectal unit.

Authors:  Annika Jacob; Wolfgang Albert; Thomas Jackisch; Christiane Jakob; Anja Sims; Helmut Witzigmann; Sören Torge Mees; Sigmar Stelzner
Journal:  Int J Colorectal Dis       Date:  2020-11-09       Impact factor: 2.571

2.  MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone.

Authors:  Xiaoxuan Jia; Peiyi Xie; Liang Bi; Xiaochun Meng; Ziqiang Wang; Nan Hong; Yi Wang
Journal:  Br J Radiol       Date:  2021-02-16       Impact factor: 3.039

Review 3.  MRI Evaluation of Complete Response of Locally Advanced Rectal Cancer After Neoadjuvant Therapy: Current Status and Future Trends.

Authors:  Qiaoyu Xu; Yanyan Xu; Hongliang Sun; Tao Jiang; Sheng Xie; Bee Yen Ooi; Yi Ding
Journal:  Cancer Manag Res       Date:  2021-06-01       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.